Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 17% Improvement Relative Risk Ventilation 67% Improvement 5% Discharge -3% van den Berg et al. NCT04516811 PROTECT-Patient Conv. Plasma RCT LATE Is late treatment with convalescent plasma beneficial for COVID-19? RCT 103 patients in South Africa (September 2020 - January 2021) Lower ventilation with convalescent plasma (not stat. sig., p=0.36) van den Berg et al., Scientific Reports, doi:10.1038/s41598-022-06221-8 Favors conv. plasma Favors control
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)
van den Berg et al., Scientific Reports, doi:10.1038/s41598-022-06221-8, PROTECT-Patient, NCT04516811 (history)
van den Berg et al., Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial.., Scientific Reports, doi:10.1038/s41598-022-06221-8, PROTECT-Patient, NCT04516811
Feb 2022   Source   PDF  
  All Studies   Meta
RCT 103 hospitalized patients in South Africa, showing no significant difference in outcomes with convalescent plasma.
risk of death, 17.0% lower, RR 0.83, p = 0.65, treatment 11 of 52 (21.2%), control 13 of 51 (25.5%), NNT 23, day 28.
risk of mechanical ventilation, 67.3% lower, RR 0.33, p = 0.36, treatment 1 of 52 (1.9%), control 3 of 51 (5.9%), NNT 25.
risk of no improvement, 5.4% lower, RR 0.95, p = 1.00, treatment 16 of 47 (34.0%), control 18 of 50 (36.0%), NNT 51, day 28.
risk of no hospital discharge, 3.0% higher, RR 1.03, p = 1.00, treatment 18 of 46 (39.1%), control 19 of 50 (38.0%), day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
van den Berg et al., 15 Feb 2022, Randomized Controlled Trial, placebo-controlled, South Africa, peer-reviewed, 30 authors, study period 30 September, 2020 - 14 January, 2021, average treatment delay 9.0 days, trial NCT04516811 (history) (PROTECT-Patient).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)
Karin Van Den Berg, Tanya Nadia Glatt, Marion Vermeulen, Francesca Little, Ronel Swanevelder, Claire Barrett, Richard Court, Marise Bremer, Cynthia Nyoni, Avril Swarts, Cordelia Mmenu, Thomas Crede, Gerdien Kritzinger, Jonathan Naude, Patryk Szymanski, James Cowley, Thandeka Moyo-Gwete, Penny L Moore, John Black, Jaimendra Singh, Jinal N Bhiman, Prinita Baijnath, Priyesh Mody, Jacques Malherbe, Samantha Potgieter, Cloete Van Vuuren, Shaun Maasdorp, Robert J Wilkinson, Vernon J Louw, Sean Wasserman
Scientific Reports, doi:10.1038/s41598-022-06221-8
There is a need for effective therapy for COVID-19 pneumonia. Convalescent plasma has antiviral activity and early observational studies suggested benefit in reducing COVID-19 severity. We investigated the safety and efficacy of convalescent plasma in hospitalized patients with COVID-19 in a population with a high HIV prevalence and where few therapeutic options were available. We performed a double-blinded, multicenter, randomized controlled trial in one private and three public sector hospitals in South Africa. Adult participants with COVID-19 pneumonia requiring non-invasive oxygen were randomized 1:1 to receive a single transfusion of 200 mL of either convalescent plasma definitive conclusions, absence of a major safety signal is somewhat reassuring. In line with experience in other settings 11 , CCP use was safe in our overall cohort, supporting future evaluation for different indications in high HIV burden populations. The premature termination of the PROTECT trial illustrates the complexity of undertaking clinical research in a rapidly evolving global pandemic. Inconsistent case numbers, viral evolution, and rapidly changing evidence during the trial period contributed to this challenge. Despite this, our trial demonstrated the feasibility of deploying CCP in a resource-limited setting and contributed knowledge on the use of this therapeutic strategy for COVID-19 pneumonia. Our experience highlights the necessity of globally networked clinical trial sites and harmonised study protocols to more efficiently evaluate interventions among diverse populations during a pandemic. Competing interests The authors declare no competing interests.
Agarwal, Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Amanat, A serological assay to detect SARS-CoV-2 seroconversion in humans, Nat. Med
Axfors, Association between convalescent plasma treatment and mortality in COVID-19: A collaborative systematic review and meta-analysis of randomized clinical trials, BMC Infect. Dis
Bajpai, Kumar, Maheshwari, Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: A pilot randomized controlled trial, medRxiv, doi:10.1101/2020.10.25
Beigel, Remdesivir for the Treatment of Covid-19-Final Report, N. Engl. J. Med
Bloch, Deployment of convalescent plasma for the prevention and treatment of COVID-19, J. Clin. Investig
Bloch, Guidance for the procurement of COVID-19 convalescent plasma: Differences between high-and low-middleincome countries, Vox Sang
Casadevall, Dadachova, Pirofski, Passive antibody therapy for infectious diseases, Nat. Rev. Microbiol
Chalmers, Abo-Leyah, Loftus, Spears, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial, Lancet
Dougan, Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2102685
Duan, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc. Natl. Acad. Sci. U. S. A
González, Regairaz, Salazar, Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumonia, medRxiv, doi:10.1101/2021.02.02
Guan, Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med
Harris, Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support, J. Biomed. Inform
Horby, Mafham, Peto, Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Horby, On behalf of the RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19, N. Engl. J. Med
Horny, of the RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19: A randomised controlled, open-label, platform trial, Lancet
Huang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Joyner, Convalescent plasma antibody levels and the risk of death from Covid-19, N. Engl. J. Med
Joyner, Safety update: COVID-19 Convalescent plasma in 20,000 hospitalized patients, Mayo Clin. Proc
Korley, Early convalescent plasma for high-risk outpatients with Covid-19, N. Engl. J. Med
Kyriazopoulou, Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial, Nat. Med
Libster, Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N. Engl. J. Med
Ling, Sim, Tan, Convalescent plasma for patients hospitalized with coronavirus disease 2019: A metaanalysis with trial sequential analysis of randomized controlled trials, Transfus Med Rev
Lundgren, On behalf of the Activ-Tico Ly-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with Covid-19, N. Engl. J. Med
Mair-Jenkins, Saavedra-Campos, Baillie, The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis, J. Infect. Dis
Marconi, Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial, Lancet Respir. Med
Moyo-Gwete, Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y.V2 (B.1.351, N. Engl. J. Med
O'donnell, A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19, J. Clin. Investig
Recovery Collaborative Group, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial, Lancet
Rojas, Convalescent plasma in Covid-19: Possible mechanisms of action, Autoimmun. Rev
Senefeld, Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency, doi:10.1101/2020.11.08
Shen, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA
Simonovich, A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N. Engl. J. Med
Tegally, Detection of a SARS-CoV-2 variant of concern in South Africa, Nature
Wibmer, SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma, Nat. Med
Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet
Zhou, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera, Cell
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop